Conference Coverage

Intranasal naloxone promising for type 1 hypoglycemia


 

REPORTING FROM ADA 2018

The study subjects were men, 43 years old, on average, with a mean body mass index of 26 kg/m2.

The investigators didn’t have any disclosures, and there was no industry funding for the work.

SOURCE: Aleksic S et al. ADA 2018, Abstract 10-LB.

Pages

Recommended Reading

Diabetes Mellitus Federal Health Data Trends (FULL)
Type 2 Diabetes ICYMI
Chronic kidney disease is 40% more common in T2DM than T1DM
Type 2 Diabetes ICYMI
Study spotlights risk factors for albuminuria in youth with T2DM
Type 2 Diabetes ICYMI
Uric acid tied to pediatric diabetic kidney disease
Type 2 Diabetes ICYMI
CANVAS data: Canagliflozin generally well tolerated up to 6.5 years
Type 2 Diabetes ICYMI
RISE: Insulin glargine, metformin offer no beta cell function benefit in youth
Type 2 Diabetes ICYMI
Fluoroquinolones can cause fatal hypoglycemia, FDA warns
Type 2 Diabetes ICYMI
Meet the rare diabetes diagnosis that thrills patients
Type 2 Diabetes ICYMI
Closed-loop insulin control for T2DM is feasible in hospital setting
Type 2 Diabetes ICYMI
Special care advised for HIV-infected patients with diabetes
Type 2 Diabetes ICYMI